Trials / Completed
CompletedNCT04449939
A Study of Subcutaneous KY1005 in Healthy Volunteers
A Phase I, Open-label Study to Assess the Pharmacokinetics of KY1005 After Single Dose Administration by Subcutaneous and Intravenous Route in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Kymab Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Single centre, open-label, single dose, parallel group study to investigate the PK, safety and tolerability of KY1005 after subcutaneous (s.c.) and intravenous (i.v.) administration, with i.v. KY1005 as a reference treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KY1005 | A human anti-OX40 ligand monoclonal antibody |
Timeline
- Start date
- 2020-07-07
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
- First posted
- 2020-06-29
- Last updated
- 2021-09-30
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04449939. Inclusion in this directory is not an endorsement.